TD Cowen maintains Buy on Vera Therapeutics, raises target to $78
TD Cowen analyst Ritu Baral maintained a Buy rating on Vera Therapeutics (NASDAQ: VERA) and increased the price target to $78 from $73, reflecting an improved assessment of the company's fundamentals and market position.
*this image is generated using AI for illustrative purposes only.
TD Cowen analyst Ritu Baral has maintained a Buy rating on Vera Therapeutics (NASDAQ: VERA) and raised the price target to $78 from the previous $73. The adjustment signals increased confidence in the company's prospects and potential for significant upside.
Rating and Target Details
The revised price target of $78 represents an increase from the prior target of $73. The Buy rating remains unchanged, indicating that the analyst expects the stock to outperform the broader market or sector averages.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $73 |
| New Price Target | $78 |
The decision to raise the target suggests an improved assessment of the company's fundamentals or market position. The maintained Buy rating implies that the firm views the risk-reward profile favorably as the company progresses towards key milestones.
What specific clinical milestones or data releases are expected to drive the stock toward the new $78 price target?
How might competitor developments in the same therapeutic area impact Vera Therapeutics' market position?
What are the potential regulatory hurdles that could affect the timeline for the company's key product approvals?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
